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Background. We aimed to analyse the morphokinetic features of breast fibrocystic changes (nonproliferative lesions, 
proliferative lesions without atypia and proliferative lesions with atypia) presenting as a non-mass enhancement (NME) 
in dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) examination.
Patients and methods. Forty-six patients with histologically proven fibrocystic changes (FCCs) were retrospectively 
reviewed, according to Breast Imaging Reporting and Data System (BI-RADS) lexicon. Prior to DCE-MRI examination, 
a unilateral breast lesion suspicious of malignancy was detected clinically, on mammography or breast ultrasonog-
raphy.
Results. The predominant features of FCCs presenting as NME in DCE-MRI examination were: unilateral regional or 
diffuse distribution (in 35 patients or 76.1%), heterogeneous or clumped internal pattern of enhancement (in 36 pa-
tients or 78.3%), plateau time-intensity curve (in 25 patients or 54.3%), moderate or fast wash-in (in 31 patients or 67.4%). 
Nonproliferative lesions were found in 11 patients (24%), proliferative lesions without atypia in 29 patients (63%) and 
lesions with atypia in six patients (13%), without statistically significant difference of morphokinetic features, except of 
the association of clustered microcysts with proliferative dysplasia without atypia.
Conclusions. FCCs presenting as NME in DCE-MRI examination have several morphokinetic features suspicious of 
malignancy, therefore requiring biopsy (BI-RADS 4). Nonproliferative lesions, proliferative lesions without atypia and 
proliferative lesions with atypia predominantly share the same predefined DCE-MRI morphokinetic features.
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 Introduction
Fibrocystic changes (FCCs) are the most frequent 
benign conditions of breast, diagnosed in 50% of 
women examined clinically and in 90% of women 
in histopathological studies. These benign disor-
ders have two important implications from the 
point of view of breast cancer diagnosis and man-
agement. First, FCCs can mimic breast cancer on 
clinical examination, mammography and breast 
ultrasonography, leading to unnecessary breast 
biopsies and patient anxiety. Second, some types 
of FCCs represent a risk factor for the subsequent 
development of breast cancer.1 Based on a classi-
fication system of FCCs proposed by Dupont and 
Page and according to other studies, women with 
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histologically confirmed nonproliferative lesions 
have no increased breast cancer risk. On the con-
trary, women whose breast biopsies show prolif-
erative lesions with or without atypia are at risk of 
developing cancer, with relative risk ranging from 
3.9–13.0 and 1.3–1.9 respectively.2-4
Combining morphological and enhancement ki-
netics features of the breast lesions, dynamic con-
trast-enhanced MRI (DCE-MRI) shows the high-
est sensitivity of all imaging methods in detecting 
breast diseases, up to 100%. Nevertheless, the spec-
ificity in the differentiation between benign and 
malignant lesions is lower, up to 75%.5 The major 
cause of false positive findings in DCE-MRI exami-
nation and consecutive unnecessary biopsies are 
the lesions with non-mass enhancement (NME). 
NME refers to the lesion that is seen only on post-
contrast DCE-MRI sequences and does not have 
space-occupying effect. The enhancement pattern 
of NME is distinct from normal surrounding breast 
parenchyma and may contain interspersed fat. On 
the contrary, a mass enhancement is a three-di-
mensional space-occupying lesion.6,7 The causes of 
NME include FCCs, inflammatory benign lesions, 
in situ ductal carcinoma (DCIS), invasive lobular 
carcinoma and some cases of oestrogen receptor-
negative invasive ductal carcinoma. The mass en-
hancement is usually confined to malignant or be-
nign tumors.8-11
Our study of pathologically confirmed FCCs 
presenting as NME in DCE-MRI examination has 
two goals: 1) to analyse morphological and en-
hancement kinetics features of FCCs, 2) to compare 
these features between nonproliferative lesions, 
proliferative lesions without atypia and prolifera-
tive lesions with atypia.
Patients and methods
Patients
In the period of two years (January 2010 to January 
2012) a total of 947 patients were examined by two 
radiologists (MZC and NMM) using the stand-
ardized breast DCE-MRI full diagnostic protocol. 
From this group, 46 patients with FCCs present-
ing as NME were selected and retrospectively re-
viewed. The study was performed in accordance 
with the Declaration of Helsinki and was approved 
by the Institutional Review Board Committee (No. 
4502-01/2011). All patients gave written informed 
consent to participate in DCE-MRI examination. 
The age of the patients was 50.78 ± 8.99 years. In all 
premenopausal women DCE-MRI was performed 
in the second and third week of the menstrual cy-
cles. None of the patients had previous breast biop-
sy, breast surgery or current hormone replacement 
therapy. All patients initially had unilateral breast 
lesion suspicious of malignancy either on clinical 
examination, mammography or ultrasonography. 
The lesions were presented as calcifications or 
asymmetric tissue on mammography and hypo-
echoic non-mass lesions on ultrasonography (BI-
RADS 4a to BI-RADS 4c categories according to the 
ACR BI-RADS lexicon).6,12 The indication for breast 
DCE-MRI prior to biopsy was to evaluate the local 
extent of the lesion in the dense breast on mam-
mography (32 patients) or suspected multifocal le-
sions on mammography and/or ultrasonography 
(14 patients).13 After the pathological confirmation 
of FCCs, the patients were examined biannually by 
physical examination and mammography. During 
the predefined follow-up period, no ipsilateral or 
contralateral breast cancer was detected. 
Methods
The DCE-MRI examinations were performed with 
a 1.5 Tesla MRI unit (Magnetom Avanto, Siemens 
Medical Solutions, Erlangen, Germany) with dedi-
cated bilateral breast coil and the patient in the 
prone position. The standard protocol was used for 
the axial-plane images with the slice thickness of 
2 mm (Table 1).14 The contrast medium was gado-
pentetate dimeglumine (Magnevist, Bayer Schering 
Pharma, Berlin, Germany) applied as the bolus in-
jection of 0.1 mmol/kg body weight injected with 
the automatic injector (Mississippi, Ulrich Medical, 
TABLE 1. Standard dynamic contrast-enhanced magnetic resonance imaging 
(DCE-MRI) protocol for axial-plane images for T1-weighted FLASH 3D precontrast 
and five postcontrast series 
T2-
weighted 
T2-
weighted 
T1-
weighted 
T1-
weighted
MRI sequence/
parameters TIRM TSE TSE FLASH 3D
Echo time (ms) 60 70 12 4.8
Repetition time 
(ms) 7690 5900 910 9.1
Inversion time (ms) 180 
Flip angle (°) 150 180 90 25
Field of view 
(mm×mm) 340×340 340×340 340×340 340×340
Image matrix 320×256 384×319 320×234 576×564
3D = three-dimensional; DCE-MRI = dynamic contrast-enhanced magnetic resonance imaging; 
FLASH = fast low-angle shot pulse sequence; TIRM = turbo inversion recovery magnitude; TSE = 
turbo spin-echo
Brought to you by | Narodna biblioteka Srbije
Authenticated
Download Date | 7/11/17 11:46 AM
Radiol Oncol 2017; 51(2): 130-136.
Milosevic ZC et al. / Breast MRI and fibrocystic changes132
Ulm, Germany) at the rate of 2 mL/s, followed by the 
flush of 20 mL saline. Contrast-enhanced dynamic 
sequences were acquired five times every 1 min 23 
s. The postprocessing methods, including a creation 
of time intensity curves (TICs), i.e. enhancement (%) 
against time (s), were performed on the worksta-
tion Leonardo, using the image processing software 
Syngo (Syngo, Siemens Medical Solutions). 
Two experienced radiologists in breast MRI, 
ZCM, 20 yr. and MMN, 7 yr., reviewed the DCE-
MRI examinations. Based on the fifth edition of the 
BI-RADS lexicon, published in 2013, the following 
morphokinetic features of NME were analysed: 
distribution of enhancement (focal, linear, segmen-
tal, regional, multiple regions, diffuse), internal en-
hancement pattern (homogeneous, heterogeneous, 
clumped, clustered ring enhancement, stippled), 
type of TICs (persistent curve or type 1, plateau 
curve or type 2, wash out curve or type 3), wash-
in i.e. the enhancement rate 90 s after intravenous 
contrast application (slow, medium, rapid), and 
signal intensity on T2-weighted (T2W) images.6 
A surgical biopsy was performed in all pa-
tients. Among them, 21 patients with nonpalable 
lesions, prior to the biopsy underwent a radiogu-
ided occult lesion localization (ROLL) procedure 
with Technetium-99m, under stereotactic or ultra-
sonographic guidance.15 Haematoxylin and eosin 
stained slides of formalin-fixed and paraffin-em-
bedded tissue blocks were assessed by a patholo-
gist, experienced in breast pathology. According to 
the classification system of Dupont and Page, the 
lesions were classified as nonproliferative lesions, 
proliferative lesions without atypia, and prolifera-
tive lesions with atypia (atypical ductal and lobular 
hyperplasia).2 
Statistical analysis
Following DCE-MRI features of NME were ana-
lysed: distribution of postcontrast enhancement, 
internal enhancement pattern, type of TICs, wash-
in, and signal intensity on T2W images. These dis-
tinctive DCE-MRI features of NME were compared 
for three groups of FCCs: nonproliferative lesions, 
proliferative lesions without atypia, and prolifera-
tive lesions with atypia. Frequencies were used to 
describe the distribution of categorical variables. 
The difference between investigated variables in 
three groups of FCCs was analysed using χ² test. 
P values less than 0.05 were considered statistically 
significant. SPSS for Windows, Statistics version 
16.0. (SPSS Inc., Chicago, USA) was used to per-
form statistical analyses.
Results 
The lesions were detected clinically in 25 patients 
(54.3%), on mammography in 43 patients (93.5%) 
and by breast ultrasonography in 30 patients 
(65.2%). 
Out of 46 biopsies, nonproliferative lesions were 
found in 11 patients (24%), proliferative lesions 
without atypia in 29 patients (63%) and prolifera-
tive lesions with atypia in six patients (13%). On 
DCE-MRI examination, all cases were presented 
as unilateral non-mass enhancement of BI-RADS 4 
category (Figure 1). 
 Forty-three lesions (93.5%) were equal to or larg-
er than 1 cm in size and three lesions were smaller 
than 1 cm and larger than 0.5 cm in size (6.5%). The 
distribution of the postcontrast enhancement was 
segmental in 11 patients (23.9%) and regional or 
diffuse in 35 patients (76.1%). The other types of 
distribution (focal, linear enhancement and multi-
ple regions) were not found. The internal enhance-
ment pattern was homogeneous in two patients 
(4.3%), heterogeneous and clumped in 36 patients 
(78.3%), and stippled in eight patients (17.4%). 
Clustered ring enhancement was not detected. 
The types of time-intensity curves were persistent 
(type 1) in 17 patients (37.0%), plateau (type 2) in 
25 patients (54.3%), and wash out (type 3) in four 
patients (8.7%). The initial postcontrast signal in-
FIGURE 1.  DCE-MRI findings of proliferative fibrocystic changes.  Axial T1-weighted 
images, precontrast image (A) and contrast-enhanced image 1 min 23 s after 
administration of gadolinium (B) with corresponding subtraction image (C), show 
the segmental, non-mass enhancement (long arrows), measured 2.5x1x2.5 cm, with 
clumped internal pattern of enhancement. Time-intensity curve is plateau (type 2) 
with fast wash-in (D).  Turbo inversion recovery magnitude (TIRM) sequence (E) show 
clustered microcysts (short arrows).
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tensity enhancement (enhancement rate, wash-in) 
was slow in 15 patients (32.6%), moderate in 14 pa-
tients (30.4%), and fast in 17 patients (37.0%). On 
T2W images FCCs were associated with clustered 
microcysts in 25 cases (54.3%).
As shown in Table 2, the features of nonprolif-
erative lesions, proliferative lesions without atypia 
and proliferative lesions with atypia on DCE-MRI 
examination did not show statistically significant 
difference in the term of the size (p = 0.454), the dis-
tribution of postcontrast enhancement (p = 0.168), 
the internal enhancement pattern (p = 0.722), the 
types of time-intensity curves (p = 0.097) and the 
initial postcontrast signal intensity enhancement (p 
= 0.752). Presence of microcysts on T2W images in 
these three groups of FCCs was statistically signifi-
cant compared to the lack of the feature (p = 0.014). 
Discussion
Numerous studies have demonstrated the clini-
cal importance of FCCs, related to the high prev-
alence of the condition, the considerable impact 
on quality of life and the increased breast cancer 
risk for women with proliferative lesions.2-4,16-18 
Nevertheless, only few studies analysed features of 
FCCs on DCE-MRI, based on the limited number 
of cases. Chen et al. reported two studies with 31 
patients and 11 patients, analysing FCCs in DCE-
MRI examination and MR spectroscopy for choline 
detection.19,20 Van den Bosch et al. and Kiyak et al. 
reported morphological and kinetic features of 
FCCs on DCE-MRI in the group of 14 patients and 
27 patients, respectively.21,22 
Our study included 46 symptomatic patients 
with pathologically confirmed FCCs presenting 
as NME, mimicking malignancy in DCE-MRI ex-
amination. Chen et al. reported that FCCs on DCE-
MRI had characteristics of NME in 39% of cases, 
mass enhancement in 35% of cases, while 26% of 
cases were nonenhancing lesions.19 According to 
the published data, breast DCE-MRI has the po-
tential to distinguish benign from malignant mass 
lesions effectively. Nevertheless, DCE-MRI is in-
ferior in discriminating benign from malignant 
NME lesions.23 Hence, a meticulous analysis of the 
multiple, standardized parameters from BI-RADS 
lexicon is crucial to achieve a higher diagnostic 
performance of DCE-MRI in the case of FCCs pre-
senting as NME, including the distribution of en-
hancement, the internal enhancement pattern, the 
TABLE 2. Nonproliferative lesion, proliferative lesions without atypia and proliferative lesions with atypia: dynamic contrast-
enhanced magnetic resonance imaging (DCE-MRI) morphological and enhancement kinetics features, based on BI-RADS lexicon
Statistical 
difference
Proliferative lesions 
without atypia (N = 6)
Proliferative lesions 
with atypia (N = 29)
Non proliferative 
lesions (N = 11)
The DCE-MRI features of fibrocystic 
changes
p = 0.454 1 1 1 0.5 < d < 1 cm Size
5 28 10 d ≥ 1 cm
p = 0.168 3 7 1 Segmental NME distribution
3 22 10 Regional or diffuse
p = 0.722 0 2 0 Homogeneous NME internal enhancement 
1 4 3 Stippled
5 23 8 Heterogeneous or clumped 
p = 0.097 3 8 6 Persistent TIC
3 19 3 Plateau
0 2 2 Wash out
p = 0.752 2 8 5 Slow Wash-in
1 10 3 Moderate
3 11 3 Fast
p = 0.014 1 18 2 Present Microcysts (T2W images)
5 11 9 Absent
d = longest diameter; DCE-MRI = dynamic contrast-enhanced magnetic resonance imaging; NME = non-mass enhancement; TIC = time-intensity curve; 
T2W = T2-weighted
Brought to you by | Narodna biblioteka Srbije
Authenticated
Download Date | 7/11/17 11:46 AM
Radiol Oncol 2017; 51(2): 130-136.
Milosevic ZC et al. / Breast MRI and fibrocystic changes134
type of TICs, the wash-in, and the signal intensity 
on T2W images. 
In our study the postcontrast enhancement of 
FCCs was unilateral in all patients. The most fre-
quent types of the distribution of NME were re-
gional - involving more than 25% of a breast quad-
rant, and diffuse - involving the entire breast (35 
patients or 76.1%). Segmental distribution, reflect-
ing the ductal distribution, was detected in 11 pa-
tients (23.9%). Thomassin-Naggara et al. emphasize 
that „the more extensive distribution of enhance-
ment is, the less suspicious for malignancy it is“.8 
Agrawal et al. showed that the diffuse enhance-
ment was highly suggestive of benign lesions.24 On 
the other hand, segmental NME was considered 
the most suspicious, with the positive predictive 
value (PPV) for malignancy from 76% to 100%, 
confirmed with the study by Tozaki and Fukuda.25 
Our results show that FCCs mainly show the more 
extensive distribution - regional and diffuse, sug-
gesting benign aetiology of the condition.
The internal pattern of enhancement in our 
study was heterogeneous and clumped in 36 cases 
(78.3%). The stippled enhancement was noted in 
eight patients (17.4%) and homogeneous in two 
patients (4.3%). According to the previous studies 
(Thomassin-Naggara et al., Tozaki and Fukuda), 
when the enhancement is heterogeneous or 
clumped the risk of malignancy is considered high, 
with the PPV of 53–58%, while the homogenous en-
hancement has low PPV for malignancy, up to 5%. 
The stippled enhancement represents the normal 
breast parenchymal enhancement.8,25 Since almost 
80% of the cases in our study showed heterogene-
ous or clumped enhancement on DCE-MRI, the 
internal pattern can be one of the most important 
reasons for mimicry of the breast cancer by FCCs.
Kinetic curve enhancement reflects functional 
aspects of blood vessel permeability in normal 
and pathological breast tissue after intravenous 
gadolinium contrast application. According to the 
published data, the permanent enhancement (type 
1 time-intensity curve) is seen in benign lesions in 
85% of cases, the plateau (type 2) curve is seen in 
36% of malignant cases and the washout (type 3) 
curve in 57% of malignant cases.26 In our study the 
majority of patients have type 2 curve (25 or 54.3%), 
followed by type 1 curve in 17 patients (37%) and 
type 3 in four patients (8.7%). Generally, the pub-
lished data about the kinetic curve enhancement 
of NME significantly differ. In the study of FCCs 
by Chen et al. 90% of NME  lesions had the type 1 
curve.19 Bartella et al. reported predominantly the 
type 2 curve in cases of malignant NME.27 Goto et 
al. did not find any differences in the kinetic curve 
enhancement between benign and malignant NME 
lesions.28 These differences may be partly due to 
the fact that the time-intensity curves are based on 
the semiquantitative analysis of gadolinium con-
trast uptake with the free-hand selected region of 
interest (ROI) on the heterogeneous areas of NME. 
Some recent studies suggested that the quantita-
tive analysis using automated computer-aided 
diagnosis (CAD) can overcome subjectivity of the 
free-hand selection of ROI.29 The postcontrast en-
hancement rate types in our study were slow in 15 
patients (32.6%), moderate in 14 patients (30.4%) 
and fast in 17 patients (37.0%). Based on the pub-
lished data, slow wash-in indicates benign lesions, 
medium wash-in may indicate lesions like mastitis, 
fresh scar, FCCs or DCIS, while the fast initial en-
hancement is suggestive of malignancy, especially 
when combined with the type 2 or the type 3 en-
hancement curve.30 
NME lesions in our study of FCCs were associ-
ated with microcysts on T2W images in 54.3% of 
cases, which was suggestive of benign conditions.8
Additionally, we investigated DCE-MRI mor-
phokinetic features of three distinct histological 
types of FCCs: nonproliferative lesions (11 cases or 
24%), proliferative lesions without atypia (29 cases 
or 63%) and proliferative lesions with atypia (6 cas-
es or 13%). Our results show that nonproliferative 
lesions, proliferative lesions without atypia and 
proliferative lesions with atypia have similar mor-
phokinetic features (distribution of NME, internal 
pattern of enhancement, type of TICs and wash-in) 
with the exception of the significant association of 
microcysts with proliferative hyperplasia without 
atypia. To our knowledge, our study is the first, 
which analyses the morphokinetic features of dis-
tinct histological types of FCCs on MRI examina-
tion. Our study was prompted by the report from 
Hartman et al. published in 2015, which anticipated 
a potentially important role of DCE-MRI in case of 
atypical hyperplasia.31 Hartman et al. showed that 
in women with atypical hyperplasia a lifetime risk 
of breast cancer approaches 30% at 25 years. This 
high cumulative incidence is not widely recog-
nized, and thus screening DCE-MRI is not routine-
ly recommended for these patients.13,32 Hartman et 
al. suggested more intensive screening of women 
with atypical hyperplasia, with DCE-MRI added 
to mammography, as well as the use of selective 
oestrogen-receptor modulators and aromatase in-
hibitors to prevent breast cancer in women with 
atypical hyperplasia. We hypothesized that the dif-
ferentiation of atypical hyperplasia by DCE-MRI 
Brought to you by | Narodna biblioteka Srbije
Authenticated
Download Date | 7/11/17 11:46 AM
Radiol Oncol 2017; 51(2): 130-136.
Milosevic ZC et al. / Breast MRI and fibrocystic changes 135
examination from other types of FCCs could be 
helpful in DCE-MRI screening. Our study was lim-
ited by the low number of proliferative lesions with 
atypia, thus necessitating further investigation. 
Our study has some limitations. We did not ana-
lyse incidental findings of FCCs on DCE-MRI. Our 
analysis was conducted in the selected group of 
symptomatic patients: the lesions were suspicious 
of malignancy on clinical examination, mammog-
raphy or ultrasonography and larger than 1 cm 
in DCE-MRI examination in 93.5% of cases. These 
facts may have influenced the interpretation and 
results of DCE-MRI examination. 
In conclusion, the profile of FCCs presented as 
NME in DCE-MRI examination predominantly in-
cludes: unilateral regional or diffuse distribution 
(76.1% of cases), heterogeneous or clumped inter-
nal pattern of enhancement (78.3% of cases), pla-
teau (type 2) time-intensity curve (54.3% of cases) 
with moderate or fast wash-in (67.4% of cases), and 
associated clustered microcysts (54.3% of cases). 
Although these findings do not have the classic 
appearance of malignancy, they are sufficiently 
suspicious to recommend the biopsy, as final BI-
RADS 4 category. In case of NME, proliferative le-
sions without atypia are the most frequent type of 
FCCs (63%), followed by nonproliferative lesions 
(24%), and proliferative lesions with atypia (13%). 
DCE-MRI cannot show the subtle histological dif-
ferences between nonproliferative lesions, prolif-
erative lesions without atypia and proliferative le-
sions with atypia. According to some novel data, 
MR diffusion-weighted imaging (DWI), related to 
tissue cellularity and thermal motion of water mol-
ecules instead of permeability of blood vessels af-
ter the contrast uptake, may be more specific than 
DCE-MRI to define the benign nature of FCCs.33,34
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